拱东医疗(605369) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was CNY 288,161,548.30, representing a year-on-year increase of 2.07%[5] - The total profit for the quarter was CNY 23,240,171.71, showing a significant decrease of 54.42% compared to the same period last year[6] - The net profit attributable to shareholders was CNY 21,615,278.21, down 53.12% year-on-year[6] - The basic earnings per share for the quarter was CNY 0.10, a decrease of 52.38% compared to the previous year[6] - The company experienced a 49.97% decline in total profit for the year-to-date compared to the same period last year[10] - Net profit for the first three quarters of 2025 was ¥71,890,298.22, down from ¥141,382,840.75 in 2024, indicating a decline of approximately 49.1%[22] - The company experienced a decrease in total comprehensive income to ¥66,810,834.59 from ¥135,771,968.77, a decline of approximately 50.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,127,116,445.47, an increase of 9.01% from the end of the previous year[6] - Current assets as of September 30, 2025, totaled RMB 1,102,686,133.56, up from RMB 865,266,163.55 at the end of 2024, indicating a significant increase in liquidity[16] - Total liabilities as of September 30, 2025, amounted to RMB 393,205,904.63, compared to RMB 233,788,763.79 at the end of 2024, indicating a significant rise in financial obligations[18] - The company's total assets reached RMB 2,127,116,445.47, up from RMB 1,951,340,242.04, reflecting a growth of approximately 9%[18] - Non-current assets decreased to RMB 1,024,430,311.91 from RMB 1,086,074,078.49, indicating a decline of about 5.7%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 149,044,625.16, reflecting a 2.38% increase[6] - The net cash flow from operating activities was ¥149,044,625.16, compared to ¥145,584,021.87 in the previous year, showing a slight increase of about 3.18%[26] - Cash and cash equivalents increased to RMB 507,913,240.40 from RMB 303,188,874.77, reflecting a growth of approximately 67.5%[16] - Cash and cash equivalents at the end of the period totaled ¥507,913,240.40, up from ¥502,874,015.62 at the end of the same period last year, reflecting a growth of approximately 1.04%[27] - The company reported a net cash outflow from investing activities of ¥42,246,685.27, compared to a net outflow of ¥30,209,819.55 in the previous year, indicating an increase in investment expenditures[27] - Cash inflow from financing activities was ¥247,132,128.00, significantly higher than ¥70,500,000.00 in the same period of 2024, representing an increase of approximately 250.5%[27] Shareholder Information - The company has a total of 11,604 common shareholders at the end of the reporting period[12] - The company reported a total of 10 major shareholders, with the largest holding 110,836,040 shares, representing a significant concentration of ownership[14] Operating Costs - Total operating costs increased to ¥752,127,483.02 from ¥683,540,594.88, marking a rise of about 10.05% year-over-year[22] Tax Expenses - The company’s tax expenses for the period were ¥7,204,990.44, down from ¥16,726,505.45 in the previous year, indicating a decrease of about 56.9%[22]